The #FierceMadness final game is set—and it’ll be GlaxoSmithKline's Trelegy taking on Boehringer Ingelheim's Ofev for the 2019 title. In Final Four action, GSK’s catchy tune and message for COPD drug ...
GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that the FDA has granted approval to its medicine Trelegy Ellipta for a new asthma indication. The FDA has approved the triple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback